Biocytogen signs Antibody Agreement with ADC Therapeutics
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) recently announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC Therapeutics a license to evaluate Biocytogen’s proprietary antibodies against three tumor targets, with an option to license selected antibodies at a later date for global ADC development and commercialization. […]
